Showing session: reset
Updates in Immuno-oncology Trials
- Sort by:
- Browse by:
- Free
- audio + slides
- All slides included
Chairperson
Michael B Atkins
Georgetown Lombardi Comp. Cancer Ctr., Washington, DC, United States
- Permission not
granted for presentation
Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Rakesh Awasthi
Novartis Institutes for BioMedical Research, East Hanover, NJ, United States
- Free
- slides video
- audio + slides
- All slides included
Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung
Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea, Republic of
- Free
- slides video
- audio + slides
- All slides included
Durvalumab + tremelimumab in patients with metastatic urothelial cancer
Arjun V Balar
Perlmutter Cancer Center at NYU Langone Health, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC
Jamie Chaft
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
Yi-Long Wu
Guandong General Hospital, Guangzhou, China
- Free
- slides video
- audio + slides
- All slides included
Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma
Denis Soulieres
Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
- Free
- slides video
- audio + slides
- All slides included
Nivolumab (Nivo) vs investigator’s choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141
Robert L Ferris
University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, United States